1887

Abstract

causes infections in humans especially in immunocompromised patients. About 80 % of nosocomial infections caused by are due to multidrug-resistant strains. The emergence of antibiotic-resistant bacterial strains necessitates the exploration of alternative antibacterial therapies, which led our group to study the ability of bacterial viruses (known as bacteriophages or simply phages) to treat mice challenged with . Phage SS specific for B5055 was isolated and characterized, and its potential as a therapeutic agent was evaluated in an experimental model of -mediated lobar pneumonia in mice. Mice were challenged by intranasal (i.n.) inoculation with bacteria (10 c.f.u. ml). A single intraperitoneal injection of 10 p.f.u. ml phage administered immediately after i.n. challenge was sufficient to rescue 100 % of animals from -mediated respiratory infections. Administration of the phage preparation 3 h prior to i.n. bacterial challenge provided significant protection in infected mice, while even 6 h delay of phage administration after the induction of infection rendered the phage treatment ineffective. The results of this study therefore suggest that the timing of starting the phage therapy after initiation of infection significantly contributes towards the success of the treatment.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.2008/002873-0
2008-12-01
2019-11-22
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/12/1508.html?itemId=/content/journal/jmm/10.1099/jmm.0.2008/002873-0&mimeType=html&fmt=ahah

References

  1. Ackermann, H. W. ( 2001; ). Frequency of morphological phage descriptions in the year. Arch Virol 146, 843–857.[CrossRef]
    [Google Scholar]
  2. Adams, M. ( 1959; ). Bacteriophages. New York: Intersciences.
  3. Bogovazova, G. G., Voroshilova, N. N. & Bondarenko, V. M. ( 1991; ). The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection. Zh Mikrobiol Epidemiol Immunobiol 4, 5–8 (in Russian).
    [Google Scholar]
  4. Bogovazova, G. G., Voroshilova, N. N., Gorbatkova, G. A., Bondarenko, V. M., Kazakova, T. B., Mamleeva, A. G., Sirnov, V. D., Glukharev, I. A., Erastova, E. I. & other authors ( 1992; ). Immunobiological properties and therapeutic effectiveness of preparations from Klebsiella bacteriophages. Zh Mikrobiol Epidemiol Immunobiol 3, 30–33 (in Russian).
    [Google Scholar]
  5. Bradley, D. E. ( 1967; ). Ultrastructure of bacteriophages and bacteriocins. Bacteriol Rev 31, 230–314.
    [Google Scholar]
  6. Carpenter, J. L. ( 1990; ). Klebsiella pulmonary infections: occurrence at one medical center and review. Rev Infect Dis 12, 672–682.[CrossRef]
    [Google Scholar]
  7. Cerveny, K. E., DePaola, A., Duckworth, D. H. & Gulig, P. A. ( 2002; ). Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect Immun 70, 6251–6262.[CrossRef]
    [Google Scholar]
  8. Chhibber, S. & Bajaj, J. ( 1995; ). Polysaccharide iron regulated cell surface protein conjugated vaccine: its role in protection against Klebsiella pneumoniae induced lobar pneumonia. Vaccine 13, 179–189.[CrossRef]
    [Google Scholar]
  9. Doern, G. V. ( 1995; ). Trends in antimicrobial susceptibility of bacterial pathogens of respiratory tract. Am J Med 99, 3S–7S.[CrossRef]
    [Google Scholar]
  10. Ellis, E. L. & Delbruck, M. ( 1939; ). The growth of bacteriophage. J Gen Physiol 22, 365–384.[CrossRef]
    [Google Scholar]
  11. File, T. M. ( 2000; ). The epidemiology of respiratory tract infections. Semin Respir Infect 15, 184–194.[CrossRef]
    [Google Scholar]
  12. Goodridge, L., Gallacci, A. & Griffiths, M. W. ( 2003; ). Morphological, host range and genetic characterization of two coliphages. Appl Environ Microbiol 69, 5364–5371.[CrossRef]
    [Google Scholar]
  13. Graybill, J. R., Marshall, L. W., Charache, P., Wallace, C. K. & Melvin, V. B. ( 1973; ). Nosocomial pneumonia. A continuing major problem. Am Rev Respir Dis 108, 1130–1140.
    [Google Scholar]
  14. Hanlon, G. W. ( 2007; ). Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents 30, 118–128.
    [Google Scholar]
  15. Hansen, D. S., Gottschau, A. & Kolmos, H. J. ( 1977; ). Epidemiology of Klebsiella bacteraemia: a case control study using Escherichia coli bacteraemia as control. J Hosp Infect 38, 119–132.
    [Google Scholar]
  16. Hervas, J. A., Alomar, A., Salva, F., Reina, J. & Benedi, V. J. ( 1993; ). Neonatal sepsis and meningitis in Mallorca Spain, 1977–1991. Clin Infect Dis 16, 719–724.[CrossRef]
    [Google Scholar]
  17. Jay, S. J. ( 1983; ). Nosocomial pneumonia. Nosocomial Infect 74, 221–223.
    [Google Scholar]
  18. Leowski, J. ( 1986; ). Mortality from acute respiratory infections in children under 5 years of age. World Health Stat Q 39, 138–144.
    [Google Scholar]
  19. Levin, B. R. & Bull, J. J. ( 1996; ). Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am Nat 147, 881–898.[CrossRef]
    [Google Scholar]
  20. Maloney, S. A. & Jarvis, W. R. ( 1995; ). Epidemic nosocomial pneumonia in the intensive care unit. Clin Chest Med 16, 209–223.
    [Google Scholar]
  21. Mathur, M. D., Bidhani, S. & Mehndiratta, P. L. ( 2003; ). Bacteriophage therapy: an alternative to conventional antibiotics. J Assoc Physicians India 51, 593–596.
    [Google Scholar]
  22. Matsuzaki, S., Rashel, M., Uchiyma, J., Ujihara, T., Kuroda, M., Ikeuchi, M., Fujieda, M., Wakiguchi, J. & Imai, S. ( 2005; ). Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 11, 211–219.[CrossRef]
    [Google Scholar]
  23. McVay, C., Velasquez, S. M. & Fralick, J. A. ( 2007; ). Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51, 1934–1938.[CrossRef]
    [Google Scholar]
  24. Meyer, K. S., Urban, C., Eagan, J. A., Berger, B. J. & Rahal, J. J. ( 1993; ). Nosocomial outbreak of Klebsiella infection resistant to late generation cephalosporins. Ann Intern Med 119, 353–358.[CrossRef]
    [Google Scholar]
  25. Nishi, T. & Tsuchiya, K. ( 1980; ). Therapeutic effects of cefotiam and cefazolin on experimental pneumonia caused by Klebsiella pneumoniae DT-S in mice. Antimicrob Agents Chemother 18, 549–556.[CrossRef]
    [Google Scholar]
  26. Podschun, R. & Ullmann, U. ( 1998; ). Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 11, 589–603.
    [Google Scholar]
  27. Sambrook, J., Fritsch, E. F. & Maniatis, T. ( 1989; ). Molecular Cloning: a Laboratory Manual, 2nd edn, 11 (2), 56–2.60. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
  28. Skurnik, M., Pajunen, M. & Kiljunen, S. ( 2007; ). Biotechnological challenges of phage therapy. Biotechnol Lett 29, 995–1003.[CrossRef]
    [Google Scholar]
  29. Soothill, J. S. ( 1992; ). Treatment of experimental infections of mice with bacteriophages. J Med Microbiol 37, 258–261.[CrossRef]
    [Google Scholar]
  30. Sulakvelidze, A., Alavidze, Z. & Morris, J. G. ( 2001; ). Bacteriophage therapy. Antimicrob Agents Chemother 45, 649–659.[CrossRef]
    [Google Scholar]
  31. Thiel, K. ( 2004; ). Old dogma, new tricks—21st century phage therapy. Nat Biotechnol 22, 31–36.[CrossRef]
    [Google Scholar]
  32. Yadav, V., Sharma, S., Harjai, K., Mohan, H. & Chhibber, S. ( 2003; ). Induction & resolution of lobar pneumonia following intranasal instillation with Klebsiella pneumoniae in mice. Indian J Med Res 118, 47–52.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.2008/002873-0
Loading
/content/journal/jmm/10.1099/jmm.0.2008/002873-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error